Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.32 USD
+0.10 (1.92%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EDIT 5.32 +0.10(1.92%)
Will EDIT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EDIT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDIT
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
EDIT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates
Other News for EDIT
EDIT, CLNE and NIU are among after hour movers
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine management to meet with Oppenheimer
Editas Medicine management to meet with Oppenheimer
Biotech Roundtable: Who will bring the next CRISPR drug to market?